Consistent with these studies, our findings indicated that troxerutin might improve hepatic glucose disorders, including the enhancement of gluconeogenesis via its anti-obesity effect and consequent elevation of circulating adiponectin in HFD-treated mouse. This evidence concerns the gene ADIPOQ and obesity disorder.